SynthesisPloS one2025
Therapeutic mechanisms of genistein in ischemic stroke: A systematic review of in vivo and in vitro studies.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genistein is an isoflavone phytoestrogen that is considered a nutraceutical compound found in soybean. The mimicking of estrogen effects includes the ability to bind to the intracellular and cell membrane receptors of estrogen and exert biological functions like antitumor, anti-inflammatory, anti-oxidative, and antiproliferative properties. With more studies focusing on the therapeutic effect of genistein, both in vitro and in vivo, it is evident that genistein acts through multiple pathways including anti-apoptotic, anti-inflammatory, and anti-oxidative. As the effects of stroke are affecting more people and causing devastating repercussions, this warrants genistein to be utilized as a therapeutic drug. Therefore, further studies are due on the effects of genistein on humans so that clinical trials can be carried out for long-term benefits. This review encompasses various studies regarding the potential neuroprotective effects of genistein on cerebral stroke, examining both in vitro and in vivo experimental models. Four database searches: Web of Science (WoS), Scopus, PUBMED and Science Direct were searched from 1st January 1999 until 31st October 2025. The initial datasets identified through the database search yielded a total of 549 publications and 341 publications were finalized after removing duplicates. In the initial screening, a total of 293 studies were excluded due to their irrelevance to the main objective of this study. After assessing the suitability of the studies and following the PRISMA guidelines, a total of 31 articles were found to be suitable and systematically reviewed. Findings demonstrated the major mechanistic pathways involved in the therapeutic action of genistein are anti-apoptotic, anti-inflammatory, and anti-oxidative. Each of these mechanisms is governed by specific pathways, which will be thoroughly discussed, indicating that genistein can be effective as a therapeutic drug in ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.